Cover Image
市場調查報告書

關鍵意見領袖(KOL)補償2015年:CEI公平市場價格年度回顧

Global Key Opinion Leader Compensation 2015: CEI's Annual Review of Fair Market Value

出版商 Cutting Edge Information 商品編碼 203459
出版日期 內容資訊 英文 99 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關鍵意見領袖(KOL)補償2015年:CEI公平市場價格年度回顧 Global Key Opinion Leader Compensation 2015: CEI's Annual Review of Fair Market Value
出版日期: 2015年02月28日 內容資訊: 英文 99 Pages
簡介

為因應醫師酬勞陽光法案、生技企業也將公平市場價格 (FMV:Fair Market Value) 流程形式化。醫療供應商正確的財務內容包括價目表標準化、清楚的KOL評分系統、定期登入值得信賴的FMV。

本報告針對關鍵意見領袖 (KOL) 公平市場價格與整體經費進行驗證、KOL報酬影響主要動向、公平市場價格(FMV:Fair Market Value)標竿、依據法令的各公司KOL報酬策略。

摘要整理

公平市場價格 (FMV:Fair Market Value) 的未來:美國陽光法案 (Sunshine Act) 與其他醫師酬勞規範回顧

  • 醫師酬勞陽光法案 (Sunshine Act) 歷史
  • 陽光法案前後環境比較
  • 醫師與業界對美國陽光法案的反應
  • 未來陽光法案與其他規管

公平市場價格率與決策

  • 公平市場價格率總計:專門家KOL
  • 公平市場價格率總計:家庭醫師、非MD供應者
  • 決定FMV因素的相互作用

KOL選擇標準影響企業層級與FMV策略

  • 為了讓選擇流程標準化而記錄KOL歷史
  • 價目表分析:理解標準化FMV背後的主因

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PH208

THE BOTTOM LINE:

In response to the Physician Payment Sunshine Act and other reporting- and rate-based legislation, life science companies have formalized their Fair Market Value (FMV) processes. Appropriate financial relationships with healthcare providers are the result of standardized rate cards, clear KOL scoring systems and regular access to reliable FMV rates.

Use Global Key Opinion Leader Compensation 2015 to stay compliant and keep pace with the rapid, worldwide formalization of FMV processes and legislation. Explore FMV rates developed from cutting-edge primary research and proprietary analytics. Understand physician tiering processes and the evolution of rate cards, and investigate the consequences of the Sunshine Act and its ex-US equivalents.

KEY QUESTIONS

ANSWERING CRITICAL QUESTIONS FOR OUR CLIENTS

This report's benchmarks and analyses address FMV values across tiers, company types, regions and activity categories for specialists, primary care physicians and non-MD providers; KOL selection factors and changes in companies' KOL scoring processes and comprehensive rate card and fee schedules. Life science executives can use Global Key Opinion Leader Compensation 2015 to stay compliant and keep pace with the rapid, worldwide formalization of FMV processes and legislation.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • What are the most relevant factors to consider when determining FMV compensation?
  • Are my company's FMV payments for specialists and non-MDs defensible and clear? How do our rates compare to other companies' compensation?
  • How do subspecialists fit into companies' FMV determination processes?
  • What criteria should companies weigh when scoring and tiering KOLs?
  • What does an effective rate card look like? How much detail should it have?
  • What factors should companies take into account when formalizing their payments?
  • What are the benefits of standardized FMV protocols, and how can companies avoid regulatory scrutiny?
  • How is the US Sunshine Act influencing transparency requirements in other markets?

KEY FINDINGS

CRITICAL FINDINGS ON GLOBAL KEY OPINION LEADER COMPENSATION

The following principles are signposts to help companies improve and enhance their fair market value processes. While these points are not inclusive of all elements in the report, they emphasize its central and most critical concepts.

  • 1. PREPARE NOW FOR UPCOMING REGULATORY MANDATES.
  • 2. CREATE FORMAL RATE CARDS AND SCORING SYSTEMS TO STANDARDIZE INTERNAL FMV PROCESSES.

Base Hourly Rates for PCPs and Non-MD Providers, by Geography

  • 3. USE RATES TO BENCHMARK YOUR FMV PAYMENTS AND GUARANTEE REGULATORY COMPLIANCE.
  • 4. USE KOL CRITERIA RATINGS TO SCORE AND TIER THOUGHT LEADERS - A PIVOTAL STEP IN FORMALIZING THE THOUGHT LEADER SELECTION PROCESS.

Table of Contents

Executive Summary

  • Key Recommendations to Ensure FMV Compliance

The Future of FMV: A Review of the US Sunshine Act and Other Physician Payment Regulations

  • The History of the Physician Payment Sunshine Act
  • That Was Then, This Is Now: A Comparative Look Between Preand Post-Sunshine Act Environments
  • Physician and Industry Reactions to the US Sunshine Act
  • The Future of the Sunshine Act and Other Regulatory Efforts

Fair Market Value Rates and Their Determination

  • Aggregated Fair Market Value Rates: Specialist Key Opinion Leaders
  • Aggregated Fair Market Value Rates: Primary Care Physicians and NonMD Providers
  • The Interplay of the Factors in Determining FMV

KOL Selection Criteria Drive Companies' Tiering and FMV Strategies

  • Score KOL's Background to Standardize Selection Process
  • Rate Card Analyses: Understanding the Key Factors Behind Standardized FMV Rates

Executive Summary

Key Recommendations to Ensure FMV Compliance

The Future of FMV: A Review of the US Sunshine Act and Other Physician Payment Regulations

  • The History of the Physician Payment Sunshine Act
    • Figure 1.1: Selected Pre-Sunshine Act District and State Physician Payment Restrictions
    • Figure 1.2: Individual States' Pre-Sunshine Act Reporting Requirements
  • That Was Then, This Is Now: A Comparative Look Between Preand Post-Sunshine Act Environments
    • Figure 1.3: US Physician Payment Sunshine Act Timeline
    • Figure 1.4: Targeted Healthcare Audiences Not Covered within Sunshine Act, by State or District-Level Governance
    • Figure 1.5: Individual States' Reporting Requirements Outside Sunshine Act's Scope
    • Figure 1.6: Loi Bertrand or French Sunshine Act
  • Physician and Industry Reactions to the US Sunshine Act
  • The Future of the Sunshine Act and Other Regulatory Efforts

Fair Market Value Rates and Their Determination

  • Aggregated Fair Market Value Rates: Specialist Key Opinion Leaders
    • Figure 2.1: Base Hourly Rates for Specialists, by Tier Designation
    • Figure 2.2: Base Hourly Rates for Specialists, by Company Type
    • Figure 2.3: Base Hourly Rates for Specialists, by Geography
    • Figure 2.4: Base Hourly Rates for Specialists for Selected Specialty Areas
    • Table 2.1: Base Hourly Rates for Selected Surgical Subspecialties
    • Figure 2.5: Hourly Rates for Specialists, by KOL Activity Category
  • Aggregated Fair Market Value Rates: Primary Care Physicians and NonMD Providers
    • Figure 2.6: Base Hourly Rates for PCPs and NonMD Providers, by Title
    • Figure 2.7: Base Hourly Rates for PCPs and NonMD Providers, by Company Type
    • Figure 2.8: Base Hourly Rates for PCPs and NonMD Providers, by Geography
    • Figure 2.9: Hourly Rates for PCPs and NonMD Providers, by KOL Activity Category
    • Table 2.2: FMV Rates for OB/GYN in Australia, Top 50 Pharma
  • The Interplay of the Factors in Determining FMV

KOL Selection Criteria Drive Companies' Tiering and FMV Strategies

  • Score KOL's Background to Standardize Selection Process
    • Figure 3.1: Types of KOLs Used, by Company
    • Figure 3.2: Average Ratings of KOL Selection Importance, by Therapeutic Area
    • Figure 3.3: Average Ratings of KOL Selection Importance, by Geography
    • Figure 3.4: Average Ratings of KOL Selection Importance, by Company Type
    • Table 3.1: Average Selection Criteria Ratings for Top 10 Companies, by Therapeutic Area
    • Table 3.2: Average Selection Criteria Ratings for Top 10 Companies, by Team Region
    • Table 3.3: Average Selection Criteria Ratings for Top 50 Companies, by Therapeutic Area
    • Table 3.4: Average Selection Criteria Ratings for Top 50 Companies, by Team Region
    • Table 3.5: Average Selection Criteria Ratings for Small Pharma Companies, by Therapeutic Area
    • Table 3.6: Average Selection Criteria Ratings for Small Pharma Companies, by Team Region
    • Table 3.7: Average Selection Criteria Ratings for Device Companies, by Therapeutic Area
    • Table 3.8: Average Selection Criteria Ratings for Device Companies, by Team Region
    • Table 3.9: Average Selection Criteria Ratings for Other Company Types, By Therapeutic Area
    • Table 3.10: Average Selection Criteria Ratings for Other Company Types, by Team Region
    • Figure 3.5: Average Percentage of KOLs within Each Tier, by Company Type
    • Figure 3.6: Average Percentage of KOLs within Each Tier, by Therapeutic Area
    • Figure 3.7: Average Percentage of KOLs within Each Tier, by Geography
    • Figure 3.8: Average Percentage of KOLs within Each Tier, by Company Type: Australia
    • Figure 3.9: Average Percentage of KOLs within Each Tier, by Company Type: Canada
    • Figure 3.10: Average Percentage of KOLs within Each Tier, by Company Type: Emerging Regions
    • Figure 3.11: Average Percentage of KOLs within Each Tier, by Company Type: Japan
    • Figure 3.12: Average Percentage of KOLs within Each Tier, by Company Type: Northern Europe
    • Figure 3.13: Average Percentage of KOLs within Each Tier, by Company Type: United States
    • Figure 3.14: Average Percentage of KOLs within Each Tier, by Company Type: Western Europe
  • Rate Card Analyses: Understanding the Key Factors Behind Standardized FMV Rates
    • Figure 3.15: Sample Rates for Advisory Board Chairs and Participants, by Company
    • Figure 3.16: Sample Rates for Speaker Program Chairs and Speakers, by Company
Back to Top